96-13978. Advisory Committee; Change of Name and Function  

  • [Federal Register Volume 61, Number 108 (Tuesday, June 4, 1996)]
    [Rules and Regulations]
    [Pages 28047-28048]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 96-13978]
    
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 14
    
    
    Advisory Committee; Change of Name and Function
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is amending the 
    standing advisory committees' regulations to change the name and the 
    function of the Fertility and Maternal Health Drugs Advisory Committee. 
    This action is being taken to more accurately describe this committee.
    
    EFFECTIVE DATE: June 4, 1996.
    
    FOR FURTHER INFORMATION CONTACT:  Donna M. Combs, Committee Management 
    Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, 
    Rockville, MD 20857, 301-443-2765.
    
    SUPPLEMENTARY INFORMATION: FDA is announcing that the name of the 
    Fertility and Maternal Health Drugs Advisory Committee has been 
    changed. After reestablishment of this committee, on March 23, 1978, 
    the agency decided that the name ``Advisory Committee for Reproductive 
    Health Drugs'' would more accurately describe the subject areas for 
    which the committee is responsible. The mandate of the committee has 
    expanded significantly in recent years to include drugs for menopausal 
    women and drugs used in the practice of andrology. The change is 
    consistent with the growing use of this term by specialists in the 
    field of reproductive health, which includes obstetrics, gynecology, 
    endocrinology,
    
    [[Page 28048]]
    
    andrology, epidemiology, and related specialties. The committee reviews 
    and evaluates data on the safety and effectiveness of marketed and 
    investigational human drugs for use in the practice of obstetrics, 
    gynecology, and related specialties.
        The Fertility and Maternal Health Drugs Advisory Committee's name 
    was changed in the charter renewal dated March 23, 1996. In this 
    document, FDA is hereby formally changing the name and the function of 
    the committee by revising 21 CFR 14.100(c)(9).
        Publication of this final rule constitutes a final action on this 
    change under the Administrative Procedure Act. Under 5 U.S.C. 
    553(b)(3)(B) and (d) and 21 CFR 10.40(d) and (e), the agency finds good 
    cause to dispense with notice and public procedure and to proceed to an 
    immediately effective regulation. Such notice and procedures are 
    unnecessary and are not in the public interest, because the final rule 
    is merely a clarifying amendment to existing regulations and when 
    effective will reflect the current committee charter. -
    
    List of Subjects in 21 CFR Part 14
    
        Administrative practice and procedure, Advisory committees, Color 
    additives, Drugs, Radiation protection.
    
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs, 21 CFR part 
    14 is amended as follows:
    
    PART 14--PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE
    
        1. The authority citation for 21 CFR part 14 continues to read as 
    follows:
    
        Authority: Secs. 201-903 of the Federal Food, Drug, and Cosmetic 
    Act (21 U.S.C. 321-394; 21 U.S.C. 41-50, 141-149, 467f, 679, 821, 
    1034; secs. 2, 351, 354, 361 of the Public Health Service Act (42 
    U.S.C. 201, 262, 263b, 264); secs. 2-12 of the Fair Packaging and 
    Labeling Act (15 U.S.C. 1451-1461); 5 U.S.C. App. 2; 28 U.S.C. 2112.
    
        2. Section 14.100 is amended by revising the heading of paragraph 
    (c)(9) and paragraph (c)(9)(ii) to read as follows:
    
    
    Sec. 14.100   List of standing advisory committees.
    
    *  *  *  *  *
        (c) *  *  *
        (9) Advisory Committee for Reproductive Health Drugs.
    *  *  *  *  *
        (ii) Function: Reviews and evaluates data on the safety and 
    effectiveness of marketed and investigational human drugs for use in 
    the practice of obstetrics, gynecology, and related specialties.
    *  *  *  *  *
    
        Dated: May 28, 1996.
    Michael A. Friedman,
    Deputy Commissioner for Operations.
    [FR Doc. 96-13978 Filed 6-3-96; 8:45 am]
    BILLING CODE 4160-01-F
    
    

Document Information

Effective Date:
6/4/1996
Published:
06/04/1996
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
96-13978
Dates:
June 4, 1996.
Pages:
28047-28048 (2 pages)
PDF File:
96-13978.pdf
CFR: (1)
21 CFR 14.100